Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Senseonics Holdings, Inc. Common Stock(SENS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SENS
11/02/2026: SENS (1-star) is currently NOT-A-BUY. Pass it for now.
Senseonics Holdings is a medical technology company known for its unique implantable continuous glucose monitoring (CGM) system, Eversense. The company's primary strength is the long-term, low-maintenance nature of its 180-day sensors, which differentiate it from standard patch-based wearables. Its main growth opportunity lies in increasing market share and securing broader insurance reimbursement for this long-term approach. However, the company faces intense competition from established giants like DexCom and Abbott, alongside significant financial risks due to ongoing operating losses. This stock is generally suited for growth-oriented investors with a high risk tolerance who are looking for exposure to niche diabetes technology and are prepared for volatility.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers a unique technological niche but faces substantial execution and dilution risks. |
| Momentum investor | Strong fit while signal remains positive | The stock is highly sensitive to news, making it a potential target when positive clinical or partnership momentum is present. |
| Value investor | Weak fit | The company is not currently profitable, making traditional valuation metrics inapplicable. |
| Dividend investor | Weak fit | The company does not pay dividends and prioritizes cash preservation for growth. |
| Low-risk investor | Weak fit | High volatility and operational uncertainty make this stock unsuitable for conservative portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is subject to extreme price swings based on clinical and funding news. |
| Valuation risk | High | High dependence on future growth makes current valuation speculative. |
| Competition risk (CGM dominance) | High | Established players have massive resources and entrenched market positions. |
| Business quality | Medium | The core technology is novel, but the business model currently relies on heavy capital infusion. |
| Dividend income | Low / none | There is no income component to the investment. |
| Execution risk | Medium / high | The company must succeed in commercializing a complex device through third-party partners. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -78.37% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/02/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 502.83M USD | Price to earnings Ratio - | 1Y Target Price 13.67 |
Price to earnings Ratio - | 1Y Target Price 13.67 | ||
Volume (30-day avg) 644.2K shares | Beta 1.03 | 52 Weeks Range 4.79 - 10.64 | Updated Date 11/01/2026 |
52 Weeks Range 4.79 - 10.64 | Updated Date 11/01/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.23 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Revenue | Revenue generated from the sale of the Eversense CGM system, primarily recognized through partner sales. | Revenue comes from selling long-term glucose monitors, often through a distribution partnership. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 21.01 | Enterprise Value 422.02M | Price to Sales(TTM) 10.36 |
Enterprise Value 422.02M | Price to Sales(TTM) 10.36 | ||
Enterprise Value to Revenue 8.69 | Enterprise Value to EBITDA 1.76 | Shares Outstanding 52.87M | Shares Floating 43.67M |
Shares Outstanding 52.87M | Shares Floating 43.67M | ||
Percent Insiders 9.87 | Percent Institutions 39.66 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.